Literature DB >> 7813855

[Relationships between plasma concentrations of endothelin and the severity of liver cirrhosis].

M Hartleb1, P Kirstetter, R Moreau, T Soupison, E Pussard, A Hadengue, P Sogni, C Gaudin, D Lebrec.   

Abstract

OBJECTIVES: Results of studies on plasma endothelin concentrations in patients with cirrhosis are conflicting. Moreover, the relationships between plasma endothelin concentrations and the severity of cirrhosis have not yet been studied. The aim of this study was to measure plasma endothelin concentrations in controls and in patients with cirrhosis. In addition, this study examined the relationships between plasma endothelin concentrations, and the severity of liver disease, splanchnic and systemic hemodynamics.
METHODS: Plasma endothelin concentrations (in the hepatic vein and the right atria), hepatic venous pressures, arterial pressure, cardiac output, pulmonary pressures and plasma concentrations of sodium and creatinine were measured in 7 controls and 28 patients with cirrhosis.
RESULTS: Plasma endothelin concentrations in the hepatic vein and the right atria were significantly higher in patients with cirrhosis (18.9 +/- 2.9 and 20.2 +/- 3.1 pg/mL, respectively) than in controls (6.1 +/- 1.1 and 7.2 +/- 1.1 pg/mL, respectively). In these patients, hepatic venous plasma endothelin concentrations were significantly correlated with Pugh's score (r = 0.49), hepatic venous pressure gradient (r = -0.44), and plasma sodium concentrations (r = -0.46). No significant correlation was found between plasma endothelin concentrations and systemic hemodynamics.
CONCLUSION: Plasma endothelin concentrations are increased in patients with cirrhosis. Moreover, this increase is more marked in patients with severe liver disease than in patients with no or moderate impairment of liver function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7813855

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  6 in total

1.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

2.  Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.

Authors:  Didier Lebrec; Jaime Bosch; Rajiv Jalan; Francis J Dudley; Rada Jessic; Richard Moreau; Juan Carlos Garcia-Pagan; Rajeshwar P Mookerjee; Eleonora Chiossi; Paul L M Van Giersbergen; Andjela Kusic-Pajic; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

3.  Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.

Authors:  Antonia Tabernero; Francis Schneider; Maria Assunta Potenza; Voahanginirina Randriamboavonjy; Sylvette Chasserot; Philippe Wolf; Delia Mitolo-Chieppa; Jean-Claude Stoclet; Ramaroson Andriantsitohaina
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

4.  Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension.

Authors:  V Chongsrisawat; P Chatchatee; R Samransamruajkit; P Vanapongtipagorn; P Chottivittayatarakorn; Y Poovorawan
Journal:  Pediatr Surg Int       Date:  2003-05-13       Impact factor: 1.827

5.  Noninvasive evaluation of portal hypertension: emerging tools and techniques.

Authors:  V K Snowdon; N Guha; J A Fallowfield
Journal:  Int J Hepatol       Date:  2012-06-07

6.  Hepatic and Plasma Endothelin-1 in Dogs with Chronic Hepatitis.

Authors:  Y Sakamoto; M Sakai; T Watari
Journal:  J Vet Intern Med       Date:  2017-03-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.